TY - JOUR
TI - Serum ceruloplasmin levels in preeclampsia: a meta-analysis
AU - Bellos, I.
AU - Papantoniou, N.
AU - Pergialiotis, V.
JO - Journal of Maternal-Fetal and Neonatal Medicine
PY - 2018
VL - 31
TODO - 17
SP - 2342-2348
PB - Taylor and Francis Ltd.
SN - 1476-7058, 1476-4954
TODO - 10.1080/14767058.2017.1340449
TODO - biological marker;  ceruloplasmin;  ceruloplasmin, clinical evaluation;  clinical practice;  comparative study;  disease course;  disease marker;  disease severity;  follow up;  human;  maternal serum;  maternal serum screening test;  pathophysiology;  preeclampsia;  pregnant woman;  priority journal;  protein blood level;  Review;  sensitivity analysis;  adult;  blood;  case control study;  female;  meta analysis;  metabolism;  preeclampsia;  pregnancy;  severity of illness index, Adult;  Case-Control Studies;  Ceruloplasmin;  Female;  Humans;  Pre-Eclampsia;  Pregnancy;  Severity of Illness Index
TODO - Purpose: To evaluate the differences in serum ceruloplasmin levels between patients with preeclampsia and healthy controls. Materials and methods: We searched the Medline (1966–2017), Scopus (2004–2017), Clinicaltrials.gov (2008–2017), Cochrane Central Register of Controlled Trials CENTRAL (1999–2017), and Google Scholar (2004–2017) databases. Meta-analysis was performed with the RevMan 5.3 software. Results: Fifteen studies were finally included in the present review, with a total number of 1927 women. Maternal serum ceruloplasmin concentration was significantly higher in preeclamptic than in the healthy pregnant women (mean differences (MD): 12.57 mg/dl, 95% CI: [8.81, 16.33]). Ceruloplasmin levels were significantly higher both in mild (MD: 13.8 mg/dl, 95% CI: [2.64, 23.53]) and severe (MD: 21.84 mg/dl, 95% CI: [0.97, 42.71]) preeclampsia, when compared to the control group. The severity of the disease did not significantly affect the levels of the protein (MD: −9.34 mg/dl, 95% CI: [−20.93, 2.26]). Conclusions: Serum ceruloplasmin may be a useful screening and follow-up tool for the evaluation of pregnant women with an indicative history of developing preeclampsia. Future studies are needed to evaluate the levels of this specific protein throughout the pregnancy course and provide data on its sensitivity and specificity by introducing cut-off values. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
ER -